Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans
Altimmune has been beaten by hepatitis B. | Altimmune has been beaten by hepatitis B. The drug candidate, which Altimmune was preparing for partnering, failed to meet the bar for further development in a phase 2 study, prompting the biotech to stop development and focus on its GLP-1/glucagon dual receptor agonist.